In order to coordinate the development of epidemic prevention and control and economic and social integration, the China National Tuberculosis Association, as the lead unit of the "Science and Innovation China" tuberculosis diagnostic technology innovation and application technology service group, has approved 23 medical transformation and innovation bases, promoting China's original science and technology Transformation of achievements and innovative development of tuberculosis prevention and treatment.
In August 2020, Shenyang Hongqi Pharmaceutical Co., Ltd. actively responded to the work of the Antituberculosis Association to expand the medical transformation innovation base unit. Our research institute, marketing department, and human resources department jointly carried out the application work, which was completed on August 30, 2020 Declare relevant materials to be submitted.
On October 24, 2020, Dr. Li Juan, Deputy General Manager, Xing Dan, Director of Marketing Department, and Zhao Weilian, Director of Government Procurement Department, represented our company to participate in the defense meeting of the Anti-Tuberculosis Association Medical Transformation Innovation Base. Shenyang Hongqi Pharmaceutical's achievements in tuberculosis prevention and treatment scientific and technological innovation, talent echelon training, and medical transformation, awards and patents in scientific and technological innovation in the past five years, domestic and foreign influence and international cooperation are fully demonstrated. After the evaluation expert group conducted on-site scoring and voting of 14 applicants, it was announced on the website of the China National Tuberculosis Association on October 26, 2020: "Agree to the "Institute of Pathogenic Biology, Chinese Academy of Medical Sciences, and the Eighth Medical Center of the Chinese Academy of Medical Sciences. The Ministry of Medicine, Tianjin Haihe Hospital, Beijing Ruixiang Biological Products Co., Ltd., and Shenyang Hongqi Pharmaceutical Co., Ltd. (listed in no particular order) are the medical transformation and innovation bases of the China National Tuberculosis Association.
Shenyang Hongqi Pharmaceutical will use the "China National Tuberculosis Association Tuberculosis Translational Medicine Innovation Base" as a platform to continue to promote the research and application of anti-tuberculosis drugs, new clinical technologies and tuberculosis prevention strategies, and actively contribute to the cause of tuberculosis prevention and treatment.
